Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Planas, Delphine; Bruel, Timothée; Grzelak, Ludivine; Guivel‐Benhassine, Florence; Staropoli, Isabelle; Porrot, Françoise; Planchais, Cyril; Buchrieser, Julian; Rajah, Maaran Michael; Bishop, Elodie; Albert, Mélanie; Donati, Flora; Prot, Matthieu; Behillil, Sylvie; Enouf, Vincent; Maquart, Marianne; Smati-Lafarge, Mounira; Varon, Emmanuelle; Schortgen, Frédérique; Yahyaoui, Layla; Gonzalez, Maria; Sèze, Jérôme De; Péré, Hélène; Veyer, David; Sève, Aymeric; Simon‐Lorière, Etienne; Fafi‐Kremer, Samira; Stéfic, Karl; Mouquet, Hugo; Hocqueloux, Laurent; Werf, Sylvie van der; Prazuck, Thiérry; Schwartz, Olivier

doi:10.1038/s41591-021-01318-5

Cited by 653 publications

(520 citation statements)

References 38 publications

Supporting

Mentioning

443

Contrasting

Order By: Relevance

“…Similarly, the South African variant, which is now spreading globally, has two escape mutations within the RBD (K417N and E484K) 24 in addition to the N501Y mutation. The combination of these three point mutations results in both a higher infection rate and reduced capacity of neutralizing antibodies produced against variants without RBD mutations of concern (hereon referred to as "wildtype") 32 . In light of these developments, and in spite of increasing data provided by vaccine companies, it remains unclear whether vaccines formulated against the original Wuhan strain of the virus will remain effective against new and emerging variants such as UK or South Africa.…”

mentioning

confidence: 99%

Immune response to SARS-CoV-2 variants of concern in vaccinated individuals

et al. 2021

View full text Add to dashboard Cite

SARS-CoV-2 is evolving with mutations in the receptor binding domain (RBD) being of particular concern. It is important to know how much cross-protection is offered between strains following vaccination or infection. Here, we obtain serum and saliva samples from groups of vaccinated (Pfizer BNT-162b2), infected and uninfected individuals and characterize the antibody response to RBD mutant strains. Vaccinated individuals have a robust humoral response after the second dose and have high IgG antibody titers in the saliva. Antibody responses however show considerable differences in binding to RBD mutants of emerging variants of concern and substantial reduction in RBD binding and neutralization is observed against a patient-isolated South African variant. Taken together our data reinforce the importance of the second dose of Pfizer BNT-162b2 to acquire high levels of neutralizing antibodies and high antibody titers in saliva suggest that vaccinated individuals may have reduced transmission potential. Substantially reduced neutralization for the South African variant further highlights the importance of surveillance strategies to detect new variants and targeting these in future vaccines.

show abstract

mentioning

confidence: 99%

Immune response to SARS-CoV-2 variants of concern in vaccinated individuals

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Although the new variant has mutations in the peak protein that is targeted by the three major vaccines (Pfizer, Moderna & AstraZeneca), they produce antibodies against various regions of the peak protein. However, over time, as more mutations emerge, the vaccines may need to be modified [11]. There is currently evidence that this variant is covered by vaccines that are currently produced by VaxzevriaTM (AstraZeneca), ModernaTM (Moderna TX, Inc) and Pfizer-BioNTechTM (Pfizer Inc & BioNTech) [4,11,12].…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 variant VUI 202012/01 (B.1.1.7) in a pediatric patient: first case report in Ecuador

Acosta-España¹,

Noboa

Ramos

et al. 2021

REV-SEP

View full text Add to dashboard Cite

Introduction: RNA viruses are known to have a high genetic variability. To date, SARS-CoV-2 has produced several variants that can change the clinical presentation of COVID-19. The first clinical case of variant B.1.1.7 with a critical clinical status in a pediatric patient is presented. It indicates that surveillance of new variants and their relationship to critical cases in pediatric patients are required. Clinical case: A pediatric patient with a history of infantile cerebral palsy, complete severe subcortical atrophy, Lennox−Gastaut syndrome, and recurrent pneumonia. She had a slow evolution requiring intensive therapy for acute respiratory distress syndrome (ARDS) that was related to SARS-CoV-2 variant B 1.1.7. Evolution: Initially, she was treated at a private hospital because she required intensive care due to ARDS, and she was then transferred to a public hospital. She was discharged after 35 days due to a favorable evolution of her infectious etiology. Conclusions: New SARS-CoV-2 variants may show new clinical behaviors. Despite this patient’s history, a clinical course towards severe symptoms had not been previously observed in pediatric patients with COVID-19. The severe symptoms could be related to the SARS-CoV-2 variant B.1.1.7 infection in this patient.

show abstract

“…However, distribution of vaccines is uneven and achieving global herd immunity may pose an extremely difficult, long-term task [63,36]. At the same time, novel variants of concern (VOC) have emerged in high prevalence regions [6,34], which may be able to reinfect individuals [21,37] and escape vaccine elicited immune responses [33,66,45]. For example, Manaus, Brazil, witnessed a massive second wave of infections [51], despite the fact that approx.…”

Section: Introductionmentioning

confidence: 99%

Rapid incidence estimation from SARS-CoV-2 genomes reveals decreased case detection in Europe during summer 2020

Smith

Trofimova

Weber³

et al. 2021

Preprint

View full text Add to dashboard Cite

By May 2021, over 160 million SARS-CoV-2 diagnoses have been reported worldwide. Yet, the true number of infections is unknown and believed to exceed the reported numbers by several fold. National testing policies, in particular, can strongly affect the proportion of undetected cases. Here, we propose a novel method (GInPipe) that reconstructs SARS-CoV-2 incidence profiles within minutes, solely from publicly available, time-stamped viral genomes. We validated GInPipe against in silico generated outbreak data and elaborate phylodynamic analyses. We apply the method to reconstruct incidence histories from sequence data for Denmark, Scotland, Switzerland, and Victoria (Australia). GInPipe reconstructs the different pandemic waves robustly and remarkably accurate. We demonstrate how the method can be used to investigate the effects of changing testing policies on the probability to diagnose and report infected individuals. Specifically, we find that under-reporting was highest in mid 2020 in parts of Europe, coinciding with changes towards more liberal testing policies at times of low testing capacities. Due to the increased use of real-time sequencing, it is envisaged that GInPipe can complement established surveillance tools to monitor the SARS-CoV-2 pandemic. We anticipate that the method is particularly useful in settings where diagnostic and reporting infrastructures are insufficient. In ‘post-pandemic’ times, when diagnostic efforts are decreased, GInPipe may facilitate the detection of hidden infection dynamics.

show abstract

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Cited by 653 publications

References 38 publications

Immune response to SARS-CoV-2 variants of concern in vaccinated individuals

Immune response to SARS-CoV-2 variants of concern in vaccinated individuals

SARS-CoV-2 variant VUI 202012/01 (B.1.1.7) in a pediatric patient: first case report in Ecuador

Rapid incidence estimation from SARS-CoV-2 genomes reveals decreased case detection in Europe during summer 2020

Contact Info

Product

Resources

About